PD-1 抑制剂获批用于 NSCLC 的新辅助治疗

{"title":"PD-1 抑制剂获批用于 NSCLC 的新辅助治疗","authors":"Redaktion Facharztmagazine","doi":"10.1007/s15004-024-0587-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"12 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-1-Hemmer bei NSCLC neoadjuvant zugelassen\",\"authors\":\"Redaktion Facharztmagazine\",\"doi\":\"10.1007/s15004-024-0587-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":503002,\"journal\":{\"name\":\"InFo Hämatologie + Onkologie\",\"volume\":\"12 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"InFo Hämatologie + Onkologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s15004-024-0587-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"InFo Hämatologie + Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s15004-024-0587-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}